Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company whose news flow centers on the development of gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases. Company press releases and SEC-referenced communications highlight regular updates on clinical trial progress, preclinical data presentations, and corporate developments.
Investors following IN8bio news can expect detailed coverage of its key programs, including INB-100 for leukemias in the post-transplant setting and DeltEx™ Drug-Resistant Immunotherapy (DRI) γδ T cells in INB-200 and INB-400 trials for newly diagnosed glioblastoma. Recent announcements describe extended median progression-free survival in GBM patients receiving repeated doses of DeltEx DRI γδ T cells, favorable safety profiles without dose-limiting toxicities, and multi-center data presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO).
News items also cover IN8bio’s γδ T cell engager pipeline, including INB-619, a CD19-targeted, pan-γδ T cell engager. The company has reported preclinical data from lupus and systemic lupus erythematosus (SLE) donor models, showing complete B cell depletion with minimal inflammatory cytokine release, and has presented these findings at conferences such as the American College of Rheumatology (ACR) Convergence Meeting and the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
In addition, IN8bio issues news releases on its proprietary manufacturing platform, scientific awards, financial results and financing transactions. Readers of INAB news can use this page to monitor clinical milestones, data readouts, scientific conference presentations and material corporate events that the company discloses through press releases and related filings.
IN8bio (Nasdaq: INAB) announced upcoming presentations of new clinical and preclinical data from its gamma-delta T cell therapies platform at major scientific conferences. The company will showcase its research at four prestigious events: AACR 2025, ISCT 2025, ASGCT 2025, and ASCO 2025.
Key presentations include:
- A novel gamma-delta T cell engager platform for cancer immunotherapy at AACR
- Manufacturing processes and TCR repertoire analysis at ISCT
- INB-600 T cell engager platform and molecular signatures at ASGCT
- Phase 1 study results of INB-200 in glioblastoma patients at ASCO
CEO William Ho emphasized the scientific rigor and clinical potential of their platform, highlighting applications in both oncology and immune-mediated diseases. The presentations will focus on their INB-200/400 program in glioblastoma and novel T cell engager technologies.
IN8bio (NASDAQ: INAB) has unveiled promising preclinical data from its gamma-delta (γδ) T cell engager (TCE) platform at AACR 2025. The company's novel platform demonstrates significant γδ T cell expansion and activation without serious side effects like cytokine release syndrome.
The platform's lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), showed potent anti-cancer activity in leukemia models at low picomolar concentrations. Unlike traditional TCEs that activate all T cells through CD3, IN8bio's platform specifically activates γδ T cells, potentially offering a safer alternative with minimal inflammatory cytokine release.
Key findings show both molecules successfully expanded Vδ1+ and Vδ2+ cell subsets and demonstrated strong cancer-killing capabilities without triggering dangerous cytokine responses. The platform's off-the-shelf nature, requiring no genetic engineering, suggests potential for scalable immunotherapy development for both cancer and autoimmune diseases.
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.
William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:
- Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
- Chairing the 'State of the IO Market, Investments and Deals Plenary'
- Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT
The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.
IN8bio (INAB) reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress in its gamma-delta T cell therapies. The company's INB-100 program demonstrated 100% long-term durable response rates in high-risk AML patients as of January 2025. The Phase 1 INB-200 trial for glioblastoma showed promising durability, with five patients remaining alive and one patient progression-free for 40.5 months.
Financial highlights include R&D expenses of $17.2M for 2024 (vs $16.8M in 2023), G&A expenses of $12.6M (vs $13.5M), and a net loss of $30.7M ($0.57 per share). The company ended 2024 with cash of $11.1M, raised additional $4.1M in February 2025, and expects runway into March 2026.
IN8bio introduced its INB-600 platform featuring a novel gamma-delta T Cell engager targeting CD19 for oncology and autoimmune diseases. The company implemented cost-saving measures and paused the Phase 2 INB-400 glioblastoma program to optimize resource allocation.
IN8bio (NASDAQ: INAB) has unveiled INB-600, a novel gamma-delta (γδ) T cell-based TCE platform designed to overcome the limitations of current γδ TCEs. The platform's first candidate, INB-619, targets CD19 for applications in leukemias, lymphomas, and autoimmune diseases.
Key preclinical findings for INB-619 include:
- Rapid B-cell depletion with γδ T cells expanding up to 450-fold
- Simultaneous activation of both Vδ1+ and Vδ2+ T cell subsets
- Lower IL-6 secretion, potentially reducing risks of cytokine release syndrome (CRS) and neurotoxicity (ICANs)
The platform represents the first known approach capable of sustained γδ T cell expansion, offering potentially greater safety and tolerability compared to current CAR-T and TCE approaches. IN8bio plans to evaluate INB-619 in preclinical studies and seek partners for future IND-enabling trials.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.
The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.
IN8bio (Nasdaq: INAB) presented Phase 1 data for INB-100, its allogeneic gamma-delta T cell therapy, showing significant promise in treating high-risk acute myeloid leukemia (AML). The data revealed zero relapses in AML patients with a median follow-up of 20.1 months. The therapy demonstrated impressive outcomes with a 90.9% progression-free survival rate and 100% overall survival at one year.
The treatment showed a favorable safety profile with no cytokine release syndrome, neurotoxicity, or dose-limiting toxicities. Evidence of in vivo expansion and long-term persistence of gamma-delta T cells was observed. With approximately 20,000 new AML cases and 11,500 deaths annually in the U.S., and post-HSCT relapse occurring in up to 50% of patients, INB-100 addresses a significant unmet medical need.
The company plans to complete enrollment of the expansion cohort in 2025, with FDA confirming relapse-free survival as an acceptable primary endpoint for a future pivotal trial.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
